Race Oncology Limited
ASX:RAC.AX
1.55 (AUD) • At close November 4, 2024
Overzicht | Financiële gegevens
Bedrijfsnaam | Race Oncology Limited |
Symbool | RAC.AX |
Munteenheid | AUD |
Prijs | 1.55 |
Beurswaarde | 264,233,150 |
Dividendpercentage | 0% |
52-weken bereik | 0.64 - 2.09 |
Industrie | Biotechnology |
Sector | Healthcare |
CEO | Dr. Peter M. Smith Ph.D. |
Website | https://www.raceoncology.com |
An error occurred while fetching data.
Over Race Oncology Limited
Race Oncology Limited operates as a precision oncology company in Australia. The company is developing Zantrene, a potent small molecule inhibitor of the fatso/fat mass and obesity associated protein to treat for melanoma and clear cell renal cell carcinoma, as well as acute myeloid leukaemia, breast, and ovarian cancers, which
Vergelijkbare Aandelen
Financiële Gegevens
Cijfers zijn in miljoenen (AUD)
Cijfers zijn in miljoenen (AUD)